SaaS entity
earnings is the sole category represented across all 1 tracked stories. Velo3D is most often covered alongside Bayer Aktiengesellschaft, which appears in 1 of these 1 story. Source depth averages 28 original sources per story, versus 5.6 across the same-window beat baseline.
Last mentioned: Feb 18, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
earnings is the sole category represented across all 1 tracked stories. Velo3D is most often covered alongside Bayer Aktiengesellschaft, which appears in 1 of these 1 story. Source depth averages 28 original sources per story, versus 5.6 across the same-window beat baseline. At 7, the average consequence score sits below the same-window beat average of 7.9. Velo3D appears in 1 tracked SaaS story from February 18, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 35 SaaS stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Velo3D. Shared-story counts are live from our verified record — not editorial picks.
A wave of Q4 earnings reports reveals a tightening fiscal environment for major players like Genmab and Santos, even as specialized biotech firms see massive gains from clinical breakthroughs. Market reactions remain erratic, with several companies experiencing share price declines despite meeting or exceeding operational targets.
Velo3D is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
